Kamada’s (KMDA) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Kamada (NASDAQ:KMDA) in a research report report published on Friday,Benzinga reports. They currently have a $11.00 price target on the biotechnology company’s stock.

Kamada Trading Up 1.2 %

Kamada stock opened at $7.41 on Friday. The firm has a market capitalization of $425.93 million, a P/E ratio of 26.46 and a beta of 0.98. The stock has a fifty day moving average price of $6.08 and a 200 day moving average price of $5.70. Kamada has a 52 week low of $4.74 and a 52 week high of $8.00.

Institutional Trading of Kamada

A hedge fund recently bought a new stake in Kamada stock. Plato Investment Management Ltd bought a new stake in shares of Kamada Ltd. (NASDAQ:KMDA) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 21,785 shares of the biotechnology company’s stock, valued at approximately $117,000. Institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.